Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidem...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermel, Melody, Lieberman, Madison, Slipczuk, Leandro, Rana, Jamal S., Virani, Salim S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963609/
https://www.ncbi.nlm.nih.gov/pubmed/36839781
http://dx.doi.org/10.3390/pharmaceutics15020459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963609/
https://www.ncbi.nlm.nih.gov/pubmed/36839781
http://dx.doi.org/10.3390/pharmaceutics15020459

Ejemplares similares